logo

COVID-19: Drugs in Development

Share

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
Trevena, Inc.
(TRVN)
TRV027
TRV027 has been selected for an National Institutes of Health (NIH)-funded ACTIV (Accelerating Covid-19 Therapeutic Interventions and Vaccines) trial in Covid-19 patients.
-
Vanderbilt University Medical Center (VUMC)
05/07/2021
Synairgen
SNG001
Positive data reported from the home cohort of SG016 Phase 2 study of SNG001 in Covid-19 patients. Also announced encouraging combined data for whole SG016 trial.
Data readout from the ongoing Phase 3 study in the second half of 2021.
-
04/30/2021
Bavarian Nordic A/S
ABNCoV2
Additional preclinical data showing the vaccine candidate's ability to induce neutralizing antibodies against SARS-CoV-2 variants, were reported.
Phase 2 study to start in the second quarter of 2021.
-
04/29/2021
Merck & Co Inc.
(MRK)
Molnupiravir
Merck signed voluntary licensing agreements with five Indian generics manufacturers including Cipla Limited, Dr. Reddy’s Laboratories Limited, Emcure Pharmaceuticals Limited, Hetero Labs Limited and Sun Pharmaceutical Industries Limited for its drug candidate Molnupiravir. Phase 3 study of Molnupiravir in non-hospitalized patients with confirmed Covid-19 is currently going on.
-
Ridgeback Biotherapeutics
04/28/2021
Kintor Pharmaceuticals
Proxalutamide
Initiated Phase 3 study of Proxalutamide in male patients with mild or moderate Covid-19 symptoms in the U.S.
-
-
04/27/2021
Medicago
Covid-19 vaccine candidate
The Interim Order (IO) rolling submission of Medicago's adjuvanted COVID-19 vaccine candidate has been accepted by Health Canada for review.
File last portion of the IO rolling submission after the Covid-19 vaccine efficacy and safety endpoint of the Phase 3 trial is reached.
-
04/26/2021
Verona Pharma plc
(VRNA)
Ensifentrine
The pilot study of a pressurized metered-dose inhaler (pMDI) formulation of ensifentrine showed that ensifentrine was well tolerated in patients hospitalized with Covid-19.
-
-
04/23/2021
Trevena, Inc.
(TRVN)
TRV027
TRV027 has been selcted to include in a Phase 2-Phase 3 trial as part of REMAP-CAP (Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia) in COVID-19 patients.
-
-
04/22/2021

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Walt Disney World, the Orlando, Florida-based entertainment complex, is easing the health safety guidelines that were rolled out to prevent the spread of the ongoing COVID-19 pandemic. The complex is ending temperature checks in a phased manner following the advice of the Centers for Disease Control and Prevention (CDC) and local health officials. Frito-Lay North America, the convenient foods division of food and beverages giant PepsiCo, Inc., is recalling select Ruffles All Dressed Potato Chips citing the possible presence of undeclared milk ingredients, a known allergen, the U.S. Food and Drug Administration said. According to the agency, the recalled products may have distributed regionally to Walmart's Sam's Club Warehouses. Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday that they have initiated the Biologics License Application (BLA) process with the U.S. Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The companies initiated...